Inhibition of PFKFB3 in a pre-clinical model of lung cancer reduced angiogenesis, decreased metastasis, enhanced barrier function, and improved drug delivery [116, 117, 136] (Fig. 4B). The gene discussed is PFKFB3; the disease is lung carcinoma.